Caliway Biopharmaceuticals マネジメント

マネジメント基準チェック /04

現在、CEO に関する十分な情報がありません。

主要情報

Yufang Ling

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	no data
CEOの所有権	11.1%
経営陣の平均在職期間	データなし
取締役会の平均在任期間	データなし

経営陣の近況

Recent updates

Companies Like Caliway Biopharmaceuticals (TWSE:6919) Can Afford To Invest In Growth

Oct 02

CEO（最高経営責任者

Yufang Ling

no data

在職期間

Ms. Yufang Ling serves as CEO and R&D Chief of Caliway Biopharmaceuticals Co. Ltd. She holds a master's degree from the Institute of Biochemistry and Molecular Biology, National Cheng Kung University Schoo...

Caliway Biopharmaceuticals マネジメント

マネジメント基準チェック /04

主要情報

経営陣の近況

Caliway Biopharmaceuticals Co., Ltd., Annual General Meeting, Jun 24, 2024

Recent updates

Caliway Biopharmaceuticals Co., Ltd. to Report Q3, 2024 Results on Nov 08, 2024

Caliway Biopharmaceuticals Completes CBL-514 Phase 2B Study (CBL-0205) for Subcutaneous Fat Reduction

Caliway Biopharmaceuticals Co., Ltd. has completed an IPO in the amount of TWD 6.480685 billion.

Caliway Biopharmaceuticals Co., Ltd. has completed an IPO in the amount of TWD 6.220454 billion.

Companies Like Caliway Biopharmaceuticals (TWSE:6919) Can Afford To Invest In Growth

Caliway Announces the Initiation of Subject Recruitment in CBL-514 Phase 2b Study for Dercum's Disease

Second quarter 2024 earnings released: NT$1.27 loss per share (vs NT$1.35 loss in 2Q 2023)

New major risk - Share price stability

First quarter 2024 earnings released: NT$1.57 loss per share (vs NT$1.06 loss in 1Q 2023)

Caliway Biopharmaceuticals Co., Ltd. Announces CBL-514 Phase 2 Study for Cellulite Treatment Met All Primary and Secondary Endpoints

Caliway Biopharmaceuticals Co., Ltd., Annual General Meeting, Jun 24, 2024

New minor risk - Share price stability

Full year 2023 earnings released: NT$3.94 loss per share (vs NT$4.89 loss in FY 2022)

New minor risk - Financial data availability

New major risk - Shareholder dilution

Caliway Biopharmaceuticals Receives U.S. FDA Fast Track Designation for CBL-514 for the Treatment of Dercum's Disease

Caliway Biopharmaceuticals Receives First Approval of CBL-514 Pivotal Phase 3 Study Application for Subcutaneous Fat Reduction

New major risk - Revenue and earnings growth

Caliway Biopharmaceuticals Announces FDA Acceptance of CBL-514 IND Application for Placebo-Controlled Phase 2 Study to Treat Dercum's Disease

Caliway Biopharmaceuticals Co., Ltd. announced that it has received $100 million in funding

Caliway Biopharmaceuticals Announces CBL-514 Phase 2 Study Topline Results for Dercum's Disease, Showing 64.5% of Lipomas with Complete Clearance or Dimensions Reduction of over 50% and Reduced Pain by 4.7

First half 2023 earnings released

Caliway Biopharmaceuticals Announces Positive Data from CBL-0201EFP Phase 2-Stage 1 Study of CBL-514 in Treating Moderate to Severe Cellulite

Caliway Biopharmaceuticals Announces Initiation of Subject Recruitment in CBL-0204 Phase 2B Study Evaluating the Efficacy of CBL-514 in Abdominal Subcutaneous Fat Reduction

CEO（最高経営責任者

在職期間

Caliway Biopharmaceuticals マネジメント

マネジメント 基準チェック /04

主要情報

経営陣の近況

Caliway Biopharmaceuticals Co., Ltd., Annual General Meeting, Jun 24, 2024

Recent updates

Caliway Biopharmaceuticals Co., Ltd. to Report Q3, 2024 Results on Nov 08, 2024

Caliway Biopharmaceuticals Completes CBL-514 Phase 2B Study (CBL-0205) for Subcutaneous Fat Reduction

Caliway Biopharmaceuticals Co., Ltd. has completed an IPO in the amount of TWD 6.480685 billion.

Caliway Biopharmaceuticals Co., Ltd. has completed an IPO in the amount of TWD 6.220454 billion.

Companies Like Caliway Biopharmaceuticals (TWSE:6919) Can Afford To Invest In Growth

Caliway Announces the Initiation of Subject Recruitment in CBL-514 Phase 2b Study for Dercum's Disease

Second quarter 2024 earnings released: NT$1.27 loss per share (vs NT$1.35 loss in 2Q 2023)

New major risk - Share price stability

First quarter 2024 earnings released: NT$1.57 loss per share (vs NT$1.06 loss in 1Q 2023)

Caliway Biopharmaceuticals Co., Ltd. Announces CBL-514 Phase 2 Study for Cellulite Treatment Met All Primary and Secondary Endpoints

Caliway Biopharmaceuticals Co., Ltd., Annual General Meeting, Jun 24, 2024

New minor risk - Share price stability

Full year 2023 earnings released: NT$3.94 loss per share (vs NT$4.89 loss in FY 2022)

New minor risk - Financial data availability

New major risk - Shareholder dilution

Caliway Biopharmaceuticals Receives U.S. FDA Fast Track Designation for CBL-514 for the Treatment of Dercum's Disease

Caliway Biopharmaceuticals Receives First Approval of CBL-514 Pivotal Phase 3 Study Application for Subcutaneous Fat Reduction

New major risk - Revenue and earnings growth

Caliway Biopharmaceuticals Announces FDA Acceptance of CBL-514 IND Application for Placebo-Controlled Phase 2 Study to Treat Dercum's Disease

Caliway Biopharmaceuticals Co., Ltd. announced that it has received $100 million in funding

Caliway Biopharmaceuticals Announces CBL-514 Phase 2 Study Topline Results for Dercum's Disease, Showing 64.5% of Lipomas with Complete Clearance or Dimensions Reduction of over 50% and Reduced Pain by 4.7

First half 2023 earnings released

Caliway Biopharmaceuticals Announces Positive Data from CBL-0201EFP Phase 2-Stage 1 Study of CBL-514 in Treating Moderate to Severe Cellulite

Caliway Biopharmaceuticals Announces Initiation of Subject Recruitment in CBL-0204 Phase 2B Study Evaluating the Efficacy of CBL-514 in Abdominal Subcutaneous Fat Reduction

CEO（最高経営責任者

在職期間

マネジメント基準チェック /04